Edit

Solasta Ventures

https://solasta-ventures.com

Last activity: 28.05.2025

Active

Invests in categories: PlatformDrugDevelopmentBioTechTechnologyProductMedtechDeliveryHealthTechLife

News

Portfolio

Persons

Mentions

Employees: 1-10

Investment Stage: Series C

Portfolio 30

Date	Name	Website	Total Raised	Location
06.05.2025	Maxion The...	maxiontherapeutics.com	$93.79M	United Kin...
08.01.2025	Axonis	axonis.us	$120M	United Sta...
04.11.2023	ReCode The...	recodetx.com	$420M	United Sta...
01.03.2023	Arcellx	arcellx.com	$324M	United Sta...
31.01.2023	Ensoma	ensoma.com	$205M	United Sta...
23.11.2021	Rescale	rescale.com	$272.4M	United Sta...
-	Rallybio, ...	rallybio.com	$182M	United Sta...
-	RAPT THERA...	rapt.com	$86M	-
-	Arvinas	arvinas.com	$114.85M	United Sta...
-	Clearside ...	clearsidebio.com	$40M	United Sta...
-	Apellis	apellis.com	$140.1M	United Sta...
-	Synlogic	synlogictx.com	$74.4M	United Sta...
-	Kymera The...	kymeratx.com	$197M	United Sta...
-	Immunitas ...	immunitastx.com	$97M	United Sta...
-	Sutro Biop...	sutrobio.com	$304.4M	United Sta...
-	HotSpot Th...	hotspotthera.com	$210M	United Sta...
-	Carisma Th...	carismatx.com	$159M	United Sta...
-	Orionis Bi...	orionisbio.com	$55M	United Sta...
-	Seer	seer.bio	$110M	United Sta...
-	x.ilio The...	xiliotx.com	$195.5M	United Sta...
-	G1 Therape...	g1therapeutics.com	$92.5M	United Sta...
-	Trefoil Th...	trefoiltherapeutics.com	$28M	United Sta...
-	Chameleon ...	chameleonbiosci.com	-	-
-	Amphivena	amphivena.com	$62M	-
-	Carbon Bio...	carbonbio.com	$38M	United Sta...
-	Bellicum P...	bellicum.com	$144.4M	United Sta...
-	Selecta Bi...	selectabio.com	$152.6M	United Sta...
-	Kezar Life...	kezarlifesciences.com	$50M	United Sta...
-	EvolveImmu...	evolveimmune.com	-	United Sta...
-	Molecular ...	mtem.com	$8.5M	United Sta...

Persons 3

Date	First Name	Last Name	Title	LinkedIn	Twitter	Email	Location
-	Michelle	Levine	Principal		-	-	-
-	Derek	Yoon	President ...		-	-	-
-	Nia	Julian	Executive ...		-	-	-

News 58

Date	Title	Description
22.05.2025	Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy	-
17.03.2025	Lilly-backed UK biotech raises $72M to advance its antibody approach	-
13.02.2025	AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal	-
19.11.2024	ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation	-
31.10.2024	AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics	-
30.10.2024	Axonis Therapeutics Announces $115 Million Series A Financing	-
15.02.2024	Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	-
21.12.2023	EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing	-
15.11.2023	Arcellx and Kite Announce Expansion In Strategic Partnership	-
20.09.2023	ReCode Raises $260M in Series B Financing to Advance Lead Programs	-
08.03.2023	Carisma Therapeutics Closes Merger with Sesen Bio	-
05.01.2023	Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines	-
12.12.2022	Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma	-
06.12.2022	AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline	-
30.09.2022	Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data	-
21.09.2022	Sesen Bio and Carisma Therapeutics Announce Merger Agreement	-
21.09.2022	Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies	-
29.06.2022	Kezar's phase 2 lupus data spur hope for former pipeline-in-a-drug contender—and a share rally	-
21.06.2022	Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field	-
09.06.2022	ASCO: ‘Any way you slice’ it, Arcellx's CAR-T is matching J&J-Legend’s Carvykti, analyst says	-
08.02.2022	Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T	-
11.01.2022	Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology	-
27.10.2021	Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™	-
25.10.2021	Xilio Therapeutics Announces Pricing of Initial Public Offering	-
06.10.2021	Takeda taps Selecta for $1.1B gene therapy research pact	-
20.08.2021	Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer	-
18.08.2021	Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline	-
27.07.2021	Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471	-
12.07.2021	Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder	-
06.07.2021	Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)	-
30.06.2021	Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis	-
28.06.2021	Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism	-
17.06.2021	Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors	-
15.06.2021	Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial	-
14.06.2021	RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial	-
07.04.2021	Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma	-
15.02.2021	FDA Approves G1 Therapeutics' Cosela to Prevent Chemo Damage in Lung Cancer	-
11.02.2021	Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer	-
07.01.2021	CARISMA THERAPEUTICS COMPLETES SERIES B FUNDING FOR $47 MILLION TO ADVANCE DEVELOPMENT OF NOVEL CAR-MACROPHAGE IMMUNOTHERAPIES	-
08.12.2020	Redwood City-based Seer's stock nearly tripled in IPO, valuing company at over $3B	-
16.11.2020	Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH	-
22.10.2020	Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19	-
28.09.2020	Atea Pharmaceuticals Fierce 15 2020 Winner	-
21.08.2020	Kymera, raising $173M+, becomes the 48th biotech IPO of the year as 2020 surpasses 2019	-
21.05.2020	HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines	-
20.05.2020	Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing	-
19.05.2020	Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020	-
09.03.2020	Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets	-
03.03.2020	Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing	-
17.12.2019	Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio	-
18.11.2019	Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants	-
12.11.2019	Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting	-
11.11.2019	Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors	-
08.11.2019	Apellis Presents Positive First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week	-
08.11.2019	Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting	-
23.10.2019	Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders	-
03.10.2019	Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform	-
29.09.2019	G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019	-

Mentions in press and media 3

Date	Title	Description
17.12.2020	Solasta Ventures Invests in Ridecell to Help Lead Digitization Movement in Mobility	Solasta Ventures Invests in Ridecell to Help Lead Digitization Movement in Mobility December 17th, 2020 \| by Diptii Tiiku, Senior Director of Corporate Marketing \| Posted in: Across The Board We recently announced our Series C financing and...
02.12.2020	Ridecell Secures $45 Million To Help Fuel Growth and Expansion	Ridecell Secures $45 Million To Help Fuel Growth and Expansion December 2nd, 2020 \| by Diptii Tiiku, Senior Director of Corporate Marketing \| Posted in: Across The Board We’re excited to announce that we have secured $45 million in our Seri...
23.08.2020	San Francisco based MedTech startup Exo raises USD 40M in series B funding	San Francisco based MedTech start-up, Exo which develops new diagnostics hardware for the medical industry announced on 20th August 2020, that it has secured USD 40M in series B funding round as investors are backing the start-ups which red...

Solasta Ventures

Portfolio 30

Persons 3

News 58

Mentions in press and media 3

Reviews 0